3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Leukemia
5
Myelodysplastic Syndromes
4
Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Graft vs Host Disease
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myasthenia Gravis
2
Leukemia, Myeloid, Acute
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Hodgkin Disease
2
Anemia, Refractory, with Excess of Blasts
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Melanoma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myeloid, Accelerated Phase
1
Leukemia, B-Cell
1
Hepatitis
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Congenital Abnormalities
1
Colitis
1
Bronchiolitis Obliterans Syndrome
1
Anemia, Refractory
1
Interventions
pembrolizumab
166
Nivolumab
111
Ipilimumab
93
Dacarbazine
44
trametinib
36
dabrafenib
34
Vemurafenib
33
binimetinib
23
atezolizumab
23
Temozolomide
21
cemiplimab
18
Paclitaxel
18
encorafenib
17
spartalizumab
16
cobimetinib
15
Carboplatin
14
talimogene laherparepvec
13
Cisplatin
13
Cyclophosphamide
12
lenvatinib
10
Pemetrexed
10
Gemcitabine
10
Docetaxel
10
durvalumab
9
Drug Therapy
9
Bevacizumab
9
tremelimumab
8
Injections
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Melanoma
×
Mycophenolic Acid
×
Clear all
NCT07619898
2026-06-02
PHOENIX-ECP
Therakos LLC
Phase 2
Not yet recruiting
112 enrolled